Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness

Slide: 23 of 34

Dual Therapy Containing Pegylated Interferon Alfa-2a Versus Dual Therapy Containing Pegylated Interferon Alfa-2b: Adverse Effects

Dual therapy with pegylated interferon alfa-2b plus ribavirin was associated with a lower risk of serious adverse events (2 trials; pooled relative risk [RR], 0.74; 95-percent confidence interval [95% CI], 0.57 to 0.95), neutropenia (5 trials; pooled RR, 0.60; 95% CI, 0.46 to 0.83), and rash (2 trials; pooled RR, 0.79; 95% CI, 0.71 to 0.88) than with dual therapy with pegylated interferon alfa-2a plus ribavirin. There were no differences in withdrawals due to adverse events.